Plus the latest iteration of the Gen 1 device is “significantly improved upon our original clinical prototype.”
This is almost the perfect quarterly report.
What a company, what a management team and what a potentially bright future.
DYOR and Not advice.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
-0.065(3.25%) |
Mkt cap ! $165.4M | |||
| Open | High | Low | Value | Volume |
| $2.00 | $2.00 | $1.94 | $102.8K | 52.37K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 150 | $1.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.94 | 2843 | 1 |
View Market Depth
| Last trade - 15.29pm 13/11/2024 (20 minute delay) ? |
| EMV (ASX) Chart |